High risk strategies for atherosclerosis

被引:28
作者
Cullen, P [1 ]
Assmann, G
机构
[1] Univ Munster, Inst Clin Chem & Lab Med, D-48129 Munster, Germany
[2] Univ Munster, Inst Arteriosclerosis Res, D-48129 Munster, Germany
关键词
coronary heart disease; risk factors; risk assessment;
D O I
10.1016/S0009-8981(99)00092-3
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 [基础医学];
摘要
Calculating a person's chances of developing coronary heart disease (CHD) is not simple, as many risk factors interact in a complex fashion. Thus many markers, though significant in univariate comparisons, are no longer so when multivariate analysis is performed. Those factors contributing independently to risk can be identified only in prospective investigations such as the Munster Heart (PROCAM) or the Framingham studies. In the Munster Heart study, follow-up of middle-aged men for eight years identified the following nine independent risk variables: age, smoking history, personal history of angina pectoris, family history of myocardial infarction, systolic blood pressure, raised plasma low density Lipoprotein cholesterol (LDL-C), low plasma high density lipoprotein cholesterol, raised fasting plasma triglyceride and presence of diabetes mellitus. These have been used to generate an algorithm for prediction of first coronary events which is available in interactive fashion on the internet(1). Large trials have shown that lowering LDL-C reduces the risk of CHD, and diminishes CHD morbidity and mortality in persons without prior evidence of coronary atherosclerosis (primary prevention). This is even more the case in patients with such evidence (secondary prevention). It appears that lowering of LDL-C also reduces all-cause mortality in secondary prevention. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:31 / 45
页数:15
相关论文
共 36 条
[1]
CHOLESTEROL AND MORTALITY - 30 YEARS OF FOLLOW-UP FROM THE FRAMINGHAM-STUDY [J].
ANDERSON, KM ;
CASTELLI, WP ;
LEVY, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (16) :2176-2180
[2]
[Anonymous], 1994, CIRCULATION
[3]
Assmann G, 1997, Eur J Med Res, V2, P237
[4]
Assmann G, 1998, EUR HEART J, V19, pA2
[5]
Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men [J].
Assmann, G ;
Schulte, H ;
vonEckardstein, A .
AMERICAN JOURNAL OF CARDIOLOGY, 1996, 77 (14) :1179-1184
[6]
Assmann G, 1996, ISRAEL J MED SCI, V32, P364
[7]
ASSMANN G, 1998, NUTR METAB CARDIOVAS, V8, P158
[8]
ASSMANN G, 1998, IN PRESS ARTERIOSCLE
[9]
Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia [J].
BakkerArkema, RG ;
Davidson, MH ;
Goldstein, RJ ;
Davignon, J ;
Isaacsohn, JL ;
Weiss, SR ;
Keilson, LM ;
Brown, WV ;
Miller, VT ;
Shurzinske, LJ ;
Black, DM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (02) :128-133
[10]
Campeau L, 1997, NEW ENGL J MED, V336, P153